We have located links that may give you full text access.
Regadenoson Reduces Soluble Receptor for Advanced Glycation End-Products in Lung Recipients.
Annals of Thoracic Surgery 2023 March 14
BACKGROUND: The selective adenosine A2A receptor (A2AR) agonist Regadenoson reduces inflammation due to lung ischemia-reperfusion injury (IRI). The objective of this study was to investigate molecular and cellular mechanisms by which regadenoson reduces IRI in lung transplant recipients.
METHODS: Fourteen human lung transplant recipients were infused for 12 hours with regadenoson and seven more served as untreated controls. Plasma levels of high mobility group box 1 and its soluble receptor for advanced glycation end-products (sRAGE) were measured by Luminex. Matrix metalloproteinass-2 and -9 (MMP-2 and MMP-9) were measured by gelatin zymography. Tissue inhibitor of metalloproteinase-1 was measured by mass spectroscopy. A2AR expression on leukocytes was analyzed by flow cytometry. MMP-9-mediated cleavage of RAGE was evaluated using cultured macrophages in vitro.
RESULTS: Regadenoson treatment during lung transplantation significantly reduced levels of MMP-9 (p<0.05), but not MMP-2, and elevated levels of Tissue Inhibitor of Metalloproteinase-1 (p<0.05), an endogenous selective inhibitor of MMP-9. Regadenoson infusion significantly reduced plasma levels of sRAGE (P<0.05) during lung reperfusion when compared with control subjects. A2AR expression was highest on iNKT cells and higher on monocytes than other circulating immune cells (p<0.05). The shedding of RAGE from cultured monocytes/macrophages was increased by MMP-9 stimulation and reduced by an MMP inhibitor or by A2AR agonists, regadenoson or ATL146e.
CONCLUSIONS: In vivo and in vitro studies suggest that A2AR activation reduces sRAGE in part by inhibiting MMP-9 production by monocytes/macrophages. These results suggest a novel molecular mechanism by which A2AR agonists reduces primary graft dysfunction.
METHODS: Fourteen human lung transplant recipients were infused for 12 hours with regadenoson and seven more served as untreated controls. Plasma levels of high mobility group box 1 and its soluble receptor for advanced glycation end-products (sRAGE) were measured by Luminex. Matrix metalloproteinass-2 and -9 (MMP-2 and MMP-9) were measured by gelatin zymography. Tissue inhibitor of metalloproteinase-1 was measured by mass spectroscopy. A2AR expression on leukocytes was analyzed by flow cytometry. MMP-9-mediated cleavage of RAGE was evaluated using cultured macrophages in vitro.
RESULTS: Regadenoson treatment during lung transplantation significantly reduced levels of MMP-9 (p<0.05), but not MMP-2, and elevated levels of Tissue Inhibitor of Metalloproteinase-1 (p<0.05), an endogenous selective inhibitor of MMP-9. Regadenoson infusion significantly reduced plasma levels of sRAGE (P<0.05) during lung reperfusion when compared with control subjects. A2AR expression was highest on iNKT cells and higher on monocytes than other circulating immune cells (p<0.05). The shedding of RAGE from cultured monocytes/macrophages was increased by MMP-9 stimulation and reduced by an MMP inhibitor or by A2AR agonists, regadenoson or ATL146e.
CONCLUSIONS: In vivo and in vitro studies suggest that A2AR activation reduces sRAGE in part by inhibiting MMP-9 production by monocytes/macrophages. These results suggest a novel molecular mechanism by which A2AR agonists reduces primary graft dysfunction.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app